| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -53,098 | -36,594 |
| Depreciation and amortization | 5,312 | 3,589 |
| Amortization of debt issuance costs and debt discount | 7,175 | 6,003 |
| Write-off of assets from clinical trials segment | 2,398 | 2,398 |
| Share-based compensation | 3,234 | 2,210 |
| Change in fair value of liability classified warrants | 246 | 96 |
| Change in fair value of liability classified conversion option derivatives | -13,273 | -7,296 |
| Unrealized loss (gain) on investments | 0 | 0 |
| Accretion of discount on investment securities | 0 | 0 |
| Deferred taxes | -32 | -32 |
| Loss on disposal of property and equipment | 0 | 0 |
| Accounts receivable | 12,949 | 8,969 |
| Other receivables | 291 | 228 |
| Inventories | 8,843 | 5,747 |
| Prepaid expenses and other current assets | -1,803 | -1,250 |
| Other assets | -3 | -3 |
| Accounts payable | 11,929 | 11,490 |
| Change in operating leases | -274 | -120 |
| Accrued expenses and other current liabilities | 2,389 | 2,262 |
| Other non-current liabilities | -95 | -97 |
| Net cash and cash equivalents used in operating activities | -27,820 | -15,190 |
| Purchases of property and equipment | 2,140 | 1,536 |
| Proceeds from asset disposition | 126 | 126 |
| Sales of marketable securities/investments | 0 | 0 |
| Net cash and cash equivalents provided by (used in) provided by investing activities | -2,014 | -1,410 |
| Proceeds from private placement, net of offering costs | 15,359 | 15,359 |
| Proceeds from at-the-market offering, net of offering costs | 9,952 | 2,340 |
| Proceeds from employee stock purchase plan | 151 | - |
| Payments made for financing of insurance payments | 691 | 456 |
| Payment of deferred consideration liability for acquisition | 0 | 0 |
| Principal payments on long-term debt | 20,000 | 20,000 |
| Principal payments on financing leases | 28 | 20 |
| Common stock issued for warrants exercised | 385 | - |
| Common stock issued for options exercised | 2,695 | - |
| Net cash and cash equivalents provided by (used in) financing activities | 7,823 | -2,777 |
| Net (decrease) increase in cash and cash equivalents | -22,011 | -19,377 |
| Cash and cash equivalents at beginning of period | 49,669 | - |
| Cash and cash equivalents at end of period | 27,658 | - |
Oncology Institute, Inc. (TOIIW)
Oncology Institute, Inc. (TOIIW)